PharmaCielo Ltd.
PCLOF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.41 | 0.04 | 0.10 |
| FCF Yield | -14.99% | -18.90% | -42.38% | -14.85% |
| EV / EBITDA | -7.28 | -3.74 | -3.52 | -5.88 |
| Quality | ||||
| ROIC | -37.68% | -58.34% | -60.25% | -89.62% |
| Gross Margin | 21.00% | -88.78% | 12.83% | -221.51% |
| Cash Conversion Ratio | 0.22 | 0.32 | 0.68 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | -13.13% | -7.45% | 26.00% | 35.21% |
| Free Cash Flow Growth | 61.87% | 50.32% | 50.98% | 24.24% |
| Safety | ||||
| Net Debt / EBITDA | -4.43 | -1.50 | -1.18 | -0.12 |
| Interest Coverage | -1.50 | -3.39 | -7.44 | -44.89 |
| Efficiency | ||||
| Inventory Turnover | 1.83 | 1.26 | 2.17 | 2.74 |
| Cash Conversion Cycle | -433.58 | -236.57 | -264.73 | -212.15 |